Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors

被引:1
|
作者
Rolin, S
Dogne, JM
Vastersaegher, C
Hanson, J
Masereel, B
机构
[1] Univ Namur, Dept Pharm, B-5000 Namur, Belgium
[2] Univ Liege, Nat & Synthet Drug Res Ctr, B-4000 Liege, Belgium
关键词
thromboxane antagonist; thromboxane synthase; pharmacological evaluation; thrombosis disorders;
D O I
10.1016/j.prostaglandins.2004.07.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this work is to evaluate the anti-thromboxane activity of two pure enantiomers of (R,S)-BM-591, a nitrobenzene sulfonylurea chemically related to torasemide, a loop diuretic. The drug affinity for thromboxane A2 receptor (TP) of human washed platelets has been determined. In these experiments, (R)-BM-591 (IC50 = 2.4 +/- 0.1 nM) exhibited a significant higher affinity than (S)-BM-591 (IC50 = 4.2 +/- 0.15 nM) for human washed platelets TP receptors. Both enantiomers were stronger ligands than SQ-29548 (IC50 = 21.0 +/- 1.0 nM) and sulotroban (IC50 = 930 +/- 42 nM), two reference TXA2 receptor antagonists. Pharmacological characterisations of (S)-BM-591 and (R)-BM-591 were compared in several models. Thus, (R)-BM-591 strongly prevented platelet aggregation induced by arachidonic acid (AA) (600 muM) and U-46619 (1 muM) while (S)-BM-591 showed a lower activity. On isolated tissues pre-contracted by U-46619, a stable TXA2 agonist, (S)-BM-591 was more potent in relaxing guinea-pig trachea (EC50 = 0.272 +/- 0.054 muM) and rat aorta (EC50 = 0.190 +/- 0.002 muM) than (R)-BM-591 (EC50 of 9.60 +/- 0.63 muM and 0.390 +/- 0.052 muM, respectively). Moreover, at 1 muM, (R)-BM-591 totally inhibited TXA2 synthase activity, expressed as TXB2 production from human platelets, while at the same concentration, (S)-BM-591 poorly reduced the TXB2 synthesis (22%). Finally, in rats, both enantiomers lost the diuretic activity of torasemide. In conclusion, (R)-BM-591 exhibits a higher affinity and antagonism on human platelet TP receptors than (S)-BM-591 as well as a better thromboxane synthase inhibitory potency. In contrast, (S)-BM-591 is more active than the (R)enantiomer in relaxing smooth muscle contraction of rat aorta and trachea guinea pig. Consequently, (R)-BM-591 represents the best candidate for further development in the field of thrombosis disorders. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 50 条
  • [1] Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors
    Soyka, R
    Guth, BD
    Weisenberger, HM
    Luger, P
    Müller, T
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) : 1235 - 1249
  • [2] THROMBOXANE SYNTHASE INHIBITORS AND RECEPTOR ANTAGONISTS
    VERMYLEN, J
    DECKMYN, H
    CARDIOVASCULAR DRUGS AND THERAPY, 1992, 6 (01) : 29 - 33
  • [3] THROMBOXANE SYNTHASE INHIBITORS AND RECEPTOR ANTAGONISTS
    COLLINGTON, EW
    FINCH, H
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1990, 25 : 99 - 108
  • [4] Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
    Kontogiorgis, C.
    Hadjipavlou-Litina, D.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (28) : 3162 - 3214
  • [5] Biological evaluation of a novel sulfonylurea. BM-531, with a dual activity on thromboxane A2 synthase and thromboxane A2 receptor
    Stéphanie, R
    Jean-Michel, D
    Jacques, D
    Bernard, M
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S108 - S108
  • [6] THROMBOXANE A2 RECEPTOR ANTAGONISTS
    HALL, SE
    MEDICINAL RESEARCH REVIEWS, 1991, 11 (05) : 503 - 579
  • [7] Pharmacological evaluation of BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent.
    de Leval, XJ
    Dassesse, T
    Benoit, V
    Pirotte, B
    Merville, MP
    David, JL
    Castronovo, V
    Dogné, JM
    BLOOD, 2003, 102 (11) : 72B - 72B
  • [8] New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors
    Cimetière, B
    Dubuffet, T
    Landras, C
    Descombes, JJ
    Simonet, S
    Verbeuren, TJ
    Lavielle, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (11) : 1381 - 1386
  • [9] THROMBOXANE SYNTHASE INHIBITORS, THROMBOXANE RECEPTOR ANTAGONISTS AND DUAL BLOCKERS IN THROMBOTIC DISORDERS
    GRESELE, P
    DECKMYN, H
    NENCI, GG
    VERMYLEN, J
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (04) : 158 - 163
  • [10] Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor
    Dogné, JM
    Wouters, J
    Rolin, S
    Michaux, C
    Pochet, L
    Durant, F
    Delarge, J
    Masereel, B
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (05) : 669 - 680